All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
Maryland Vol.9 (corporations: Novavax)
上記リンク内に無い本日までのツイート
This morning, we provided an update related to Phase 3 development of our #COVID-19 #vaccine candidate. We are pleased to share that our pivotal Please 3 trial in the UK is being expanded to 15,000 volunteers. Please read our news release here: https://t.co/d2KVr0KAvo $NVAX pic.twitter.com/mEiO5x2PRK
— Novavax (@Novavax) October 27, 2020
Novavax delays U.S. trial of COVID-19 vaccine candidate to November https://t.co/CwpxuwnHhC pic.twitter.com/tlsawilQnx
— Reuters (@Reuters) October 27, 2020
Covid-19 vaccine: Novavax delays US clinical trials to Novemberhttps://t.co/R6MhC6NVjf pic.twitter.com/I7wdk2F9Jk
— Mint (@livemint) October 27, 2020
Data from an early-to-mid stage trial of the vaccine is expected on Friday, the company said. Earlier data had shown the vaccine produced high levels of antibodies against the novel coronavirus.#covid19 #coronavirusvaccine #UStrial #novavax
https://t.co/dXEIk7KCic— CNBC-TV18 (@CNBCTV18News) October 28, 2020
Novavax delays US trial of COVID-19 vaccine candidate to November https://t.co/YMGnO6n8up
— The Tribune (@thetribunechd) October 27, 2020
Novavax Delays US Trial Of #COVID19Vaccine Candidate To November https://t.co/5PSEM9QpfV pic.twitter.com/TRk8t7SHa0
— NDTV (@ndtv) October 27, 2020
Novavax expects its U.S. Phase Three clinical trial to begin by the end of November. https://t.co/Al3X0QYcLR
— WJZ | CBS Baltimore (@wjz) October 27, 2020
$NVAX Novavax Shares Jump After Coronavirus Vaccine Trial Updatehttps://t.co/axH7XPkjWq
— Top Stock Alerts (@TopStockAlerts1) October 27, 2020
FREE TO READ | CORONAVIRUS BLOG
— Novavax's U.S. vaccine trial won't start until November
— India sees lull in new cases
— No pub crawls, Japanese governor sayshttps://t.co/EIthN9I75m— Nikkei Asia (@NikkeiAsia) October 27, 2020
Novavax delays U.S. trial of Covid-19 vaccine candidate to November $NVAX $PFE $AZN-GB https://t.co/VWVLoKSnij
— Healthcare News (@HealthcareBeat) October 27, 2020
$NVAX Novavax expands late-stage UK trial for COVID-19 vaccine candidate to 15,000 volunteers https://t.co/kITh9ocOz3 via @proactive_UK #NVAX
— Ruth Gemmell (@ruth_proactive) October 27, 2020
Covid vaccine, Novavax, delay rumours, weighing on sentiment By @ross_burland https://t.co/yJjp4PgX8b #Coronavirus #Equities #Politics
— FXStreet News (@FXstreetNews) October 26, 2020
An alphabet soup of potential COVID-19 vaccines presented by Dr Gerald Evans, Chair ID @QueensuDOM @KingstonHSC. Several in phase 3-Astra Zeneca, Can-Sci, Pfizer, Moderna & Novavax- stimulate neutralizing antibodies at levels like those in convalescent serum pic.twitter.com/LKwZ4xikJ8
— Stephen L. Archer (@DrStephenArcher) October 27, 2020
All ready for our last #novavax vaccine trial day – almost 500 fantastic volunteers have been vaccinated. Awesome team @CityOfResearch @SaralayaD @BTHFT @BiBresearch pic.twitter.com/XoGoOZvCul
— John Wright (@docjohnwright) October 26, 2020
I’m in the phase 3 Novavax vaccine study and so far it’s been relatively painless (blood testing, injection, covid swab etc). They need more volunteers from a range of demographics to test its effectiveness and immune responses. Register here if you can: https://t.co/362g21Z2Zv pic.twitter.com/6d8BxTDci0
— Sarah Jankowitz (@SarahJankowitz) October 26, 2020
Earlier today, I got a shot as part of the Novavax Covid-19 vaccine trial (phase 3). Been more than an hour and I feel fine. In three weeks, I'll get a second shot.
Many thanks to @RoyalFreeNHS & @iit_ucl.
You too can be a part of helping science. https://t.co/Uoii7jJLvr
— Akshat Rathi (@AkshatRathi) October 23, 2020
We are proud that @Keele_CTU is supporting the @NIHRresearch regional site in a study to test the effectiveness of the Novavax Covid-19 vaccine candidate ⬇️ https://t.co/O7AnznKGW6
— Keele University (@KeeleUniversity) October 22, 2020
COVID-19 Vaccine updates:
– Pfizer and Moderna in Phase 3 trials; they may be ready to apply for emergency FDA authorization in late November.
– Johnson & Johnson on pause. Astrazeneca on FDA hold.
– Novavax to start Phase 3 as soon as this month. pic.twitter.com/b2lyWDHUAM— Randz (@RH4N6) October 21, 2020
An extraordinary structural, biophysical, and antigenic characterization of the @novavax vaccine spike protein and glycanshttps://t.co/3qeRtUNJuX
Just published @ScienceMagazine
Proud of @Sandhyareddy88 and my @scrippsresearch colleagues who did this work pic.twitter.com/e5UBuw0zE5— Eric Topol (@EricTopol) October 20, 2020
high hopes for the novavax subunit vaccine. Nice cryo-EM work from my @WardLab1 colleagues. https://t.co/gqUklJHLzE
— ZackB (@zacharyberndsen) October 20, 2020
awesome stuff, I'm on the novavax phase 3 trials that just started in uk. got my first shot last week.
— chipped (@chipped1) October 19, 2020
World leading research: NIHR's new National Patient Recruitment Centres (NPRCs) are playing a leading role in delivering #Covid19 vaccine research, with the world's first participant to join the @Novavax phase 3 vaccine trial recruited at Blackpool NPRC https://t.co/seAwKjXsNp pic.twitter.com/o6rWgzIXUr
— NIHR Research (@NIHRresearch) October 19, 2020
$NVAX Novavax. Currently in Previous Month Low Pivot range. 85 area of confluence for both Monthly S1 floor Pivot and Monthly Camarilla L4. Could be a potential reversal area to keep an eye on. pic.twitter.com/FhpGrTUKkE
— Pivot Investor (@pivotinvestor) October 27, 2020
$NVAX Novavax's stock rises 3% as it announces plans to share Phase 2 vaccine data this week https://t.co/44CU9SwBDn
— Biomed & Tech Stock Focus (@MarcJacksonLA) October 27, 2020
Novavax's stock rises 3% as it announces plans to share Phase 2 vaccine data this week https://t.co/lanQONwG2A
— MarketsTicker (@MarketsTicker) October 27, 2020
The Research Team at @NTHFTResearch are still recruiting to the NOVAVAX Vaccine Study at Hartlepool Hospital
If you meet the criteria, & want to help find a #COVID19 vaccine, enrol using the link below and book an appointment as soon as next week#BePartOfResearch #ResearchNENC https://t.co/CuKSQURDxZ
— NIHR CRN North East and North Cumbria (@NIHRCRN_NENCumb) October 22, 2020
$NVAX Novavax call volume above normal and directionally bullish pic.twitter.com/mIrEZDlVfL
— Maria Chaudhry (@mchaudhry82) October 20, 2020
Novavax $NVAX makes vaccines by sticking proteins onto microscopic particles; their flu vaccine finished Phase 3 trials in March. The company launched trials for a Covid-19 vaccine in May, in July the U.S. government awarded $1.6 billion to support the vaccine’s clinical trials. https://t.co/7wiLh1aGbA
— artificial mustaches (@artmustaches) October 20, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines https://t.co/ZES9ZrOmIz pic.twitter.com/0dUg7UjM6Z
— Reuters (@Reuters) August 7, 2020
https://twitter.com/Reuters/status/1291764717330071557
Japan in deals with AstraZeneca, Novavax for Covid-19 vaccines https://t.co/32k1B24nye
— The Straits Times (@STcom) August 7, 2020
Covid-19 roundup: Novavax inks vaccine deals with Japan and India; AstraZeneca nearing agreements with Japan and Brazil https://t.co/1Gnd5TUZMe
— Endpoints News (@endpts) August 7, 2020
Novavax taps Japan's AGC to make ingredient in COVID-19 shot https://t.co/Drdp3TuRB7 #coronavirus #vaccine #pharma $NVAX
— Nikkei Asia (@NikkeiAsia) June 4, 2020
Japan is very selective. Why did they choose Novavax and their Sars-CoV-2 candidate? https://t.co/BGWVmtFIyQ
— Jeffrey A. Hirschfield, MD, DipABLM (@DrHirschfield) August 11, 2020
$Nvax Novavax Inks Vaccine Deals In Japan, India; Analyst Sees 70% Stock Upside
Follow us @WebullGlobal
https://t.co/AYixzJLFgR— Kyrell Fontaine (@KkFontaine23) August 10, 2020
Novavax Inks Vaccine Deals In Japan, India; Analyst Sees 70% Stock Upsidehttps://t.co/OufJCpbrW6 $NVAX $TAK
— TipRanks (@TipRanks) August 9, 2020
Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines https://t.co/jnSEVdnzRX
— SpeedyRalph (@RalphSpeedy) August 9, 2020
Fujifilm to supply Novavax with key part of COVID vaccine https://t.co/ki25NgUjXZ #IndoPacific #Fujifilm #Novavax #COVID19 #Vaccine #Japan
— Indo-Pacific Defense FORUM (@IPDefenseForum) July 24, 2020
$NVAX is pleased to announce a partnership with global vaccine leader @Takeda to develop, manufacture & commercialize our #COVID19 vaccine candidate, #NVXCoV2373, in Japan. To learn more, please read today's announcement here: https://t.co/QhbV2LVUBC pic.twitter.com/iSDc9EraHp
— Novavax (@Novavax) August 7, 2020
As a global pharmaceutical company it is our responsibility to support efforts to help protect people from #COVID19. This is why our partnership with @Novavax on their COVID-19 vaccine candidate in Japan is so important to us. Read more here: https://t.co/nl4FCxrlkC pic.twitter.com/AoU8AFRe4e
— Takeda (@TakedaPharma) August 10, 2020
Today, we announced a collaboration with @Novavax for the development, manufacturing and commercialization of the company's #COVID19 #vaccine candidate in Japan. Read the full release here: https://t.co/P6k0JYLAkx pic.twitter.com/cmPVlaJ30V
— Takeda (@TakedaPharma) August 7, 2020
Takeda to make Novavax's COVID-19 vaccine candidate in Japan https://t.co/1AFganqthk pic.twitter.com/L99scxnKI8
— Reuters Business (@ReutersBiz) August 7, 2020
Takeda to make Novavax's COVID-19 vaccine candidate in Japan https://t.co/v99Uu2hR2s pic.twitter.com/SlYBoO5ap4
— Reuters (@Reuters) August 7, 2020
Pharmaceutical giant @TakedaPharma will help startup @Novavax commercialize its #COVID19 vaccine in Japan. The drugmaker anticipates manufacturing 250 million doses per year and the first batches of the vaccine will be ready in 2021 https://t.co/0EKQ7NCAMD
— MassEcon (@MassEcon) August 18, 2020
Takeda collaborates with #Novavax for COVID 19 vaccine in Japan. Read More: https://t.co/cqNwwjGRx8
— investmedical (@investmedical) August 17, 2020
8-13-2020: In Japan, the Novavax/Fujifilm vaccine will be made by Takeda. In South Korea, the Novavax/Fujifilm vaccine will be made by SK Bioscience:https://t.co/ndgoO19YTthttps://t.co/N3l2kzeesShttps://t.co/9gYAMfHPYKhttps://t.co/M0ig6pMvrUhttps://t.co/eqCJzUBYSq
— Ronald M. Chavin (@rmchavin) August 13, 2020
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japanhttps://t.co/CdDsBOTJzl#news #pharma #pharmiweb
— Pharma News (@pharminews) August 13, 2020
Takeda and Novavax are partnering on manufacturing COVID‑19 vaccine candidate https://t.co/e6AHf5G2SL via @GMP news #coronavirus #vaccine #COVID19 #Takeda #GMPNews
— GMPnews.Net (@GMPnewsNet) August 10, 2020
Novavax announces a deal with Takeda to manufacture and distribute its #COVID19 vaccine in Japan. The Phase 3 trial of the vaccine is expected to begin this fall. $NVAX $TAKhttps://t.co/NmTzfxt0aF
— Microbial Biotech News (@MicrobialNews) August 9, 2020
Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan https://t.co/q6uz9o0ux2
— cafepharma (@cafepharma) August 9, 2020
Takeda strikes deal to bring Novavax' NVX‑CoV2373 COVID-19 vaccine to Japan #Takeda #Novavax #Japan #Covid-19 #coranavirus #NVX‑CoV2373 #pharmanews #vaccine https://t.co/o36Js4vWHc
— OyeCricket.com (@cricket_fundas) August 8, 2020
#NVAX Novavax Partners With Takeda for Japan Output of Covid Drug https://t.co/Wx0HRgz0C2
— Emanuele Orsili (@emanueleorsili) August 7, 2020
Takeda Pharmaceutical Co. said Friday it will produce and sell in Japan a COVID-19 vaccine being developed by U.S. biotechnology firm Novavax Inc.https://t.co/xXoi1wqU4u
— Jeffs (@jeffs_araujo35) August 7, 2020
@TakedaPharma to supply @Novavax's #coronavirus vaccine candidate in Japan https://t.co/utm8bO9xNW pic.twitter.com/qWtykeLinR
— BioBuzz (@BioBuzzMaryland) August 7, 2020
These look like strong results:
– the antibody levels for the adjuvant groups were at least 100x over the non-adjuvant ones
– neutralizing antibodies were 4x those seen in #COVID19 convalescent serumhttps://t.co/jY54SR1EBl— EPIDATUM (@epidatum) August 7, 2020
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan! Government of Japan to provide funding to Takeda for tech transfer and scale-up of manufacturing! $NVAX $TAK #COVID19 #coronavirus #vaccinehttps://t.co/91240ADASi pic.twitter.com/sjAs5FCdT2
— AlphaBronze (@Alpha_Bronze) August 7, 2020
$NVAX and Takeda Announce Collaboration for Novavax’ #COVID19 Vaccine Candidate in Japan. $TAK https://t.co/zpCtBMl2sK
— Bio Stocks™ (@BioStocks) August 7, 2020
The Latest Info On Pharmaceutical Treatments And #Vaccines•#GileadSciences•#AbbVie•#Moderna•Johnson&Johnson•#EliLilly•#Pfizer•#GlaxoSmithKline•#VirBiotechnology•#Sanofi•Apeiron Biologics•#CureVac•#Dyadic•#Mesoblast•#Novavax•#Roche•#Takeda https://t.co/De0VjosMjf
— LebensKünstler (@GmmLhDBsc2heyst) March 20, 2020
U.S. Flu Vaccine Market @SanofiPasteur, @gsk, @Seqirus, @CSLLimited, @AstraZeneca, @Mylan, @BioDiem, @Novavax, @BiondVax, @Medicago, @Moderna, @Pneumagen, @Daiichi–Sankyo, @Altimmune, @FluGen, @Imutex #flu https://t.co/Bd1Cnao6Hb via @dpiresearch
— DPI Research (@DPIResearch) October 5, 2020
United States Influenza Vaccines Market 2018-2025 Analysis by emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca https://t.co/qQqrKL10Fm via @openPR
— DPI Research_Vaccine (@MarketR_Vaccine) November 5, 2018
United States Shingles Vaccine Market https://t.co/SiApsaGBM1 @SanofiPasteur,@GSK,@Seqirus,@CSL Limited,@AstraZeneca,@Mylan,@GammaVaccines,@Hualan,@ShanghaiInstitute,@BioDiem,@Novavax,@BiondVax,@Medicago,@Moderna,@Pneumagen,@Daiichi–Sankyo,@Altimmune,@FluGen,@Imutex
— DPI Research Official (@dpi_research) September 2, 2020
